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Background. Ventilator-associated pneumonia (VAP) is the most common health care-associated infection. To prevent this
complication, aspiration of subglottic secretions using Hi-Lo Evac endotracheal tube (Evac ETT) is a recommended intervention.
However, there are some reports on Evac ETT dysfunction. We aimed to compare the incidence of VAP (per ventilated patients)
in severely ill poisoned patients who were intubated using Evac ETT versus conventional endotracheal tubes (C-ETT) in our
toxicology ICU.Materials andMethods. In this clinical randomized trial, 91 eligible patientswith an expected duration ofmechanical
ventilation of more than 48 hours were recruited and randomly assigned into two groups: (1) subglottic secretion drainage (SSD)
group who were intubated by Evac ETT (𝑛 = 43) and (2) control group who were intubated by C-ETT (𝑛 = 48). Results. Of the
91 eligible patients, 56 (61.5%) were male. VAP was detected in 24 of 43 (55.8%) patients in the case group and 23 of 48 (47.9%)
patients in the control group (𝑃 = 0.45). The most frequently isolated microorganisms were S. aureus (54.10%) and Acinetobacter
spp. (19.68%).The incidence of VAP and ICU length of stay were not significantly different between the two groups, but duration of
intubation was statistically different and was longer in the SSD group. Mortality rate was less in SSD group but without a significant
difference (𝑃 = 0.68). Conclusion. The SSD procedure was performed intermittently with one-hour intervals using 10 mL syringe.
Subglottic secretion drainage does not significantly reduce the incidence of VAP in patients receiving MV.This strategy appears to
be ineffective in preventing VAP among ICU patients.
1. Introduction
Ventilator-associated pneumonia (VAP) is themost common
health care-associated infection defined as the involvement of
the lung parenchyma that occurs more than 48 hours after
intubation and initiation of mechanical ventilation (MV)
[1, 2]. VAP increases intensive care unit (ICU) and hospital
length of stay and increases costs by at least six days and
m12 000 per patient episode [2]. Highmorbidity andmortality
rates of VAP patients have already been reported in several
investigations [1–6]. Due to the association of VAP and
poor outcomes, VAP prevention is an important topic on
the research agenda of ICU clinicians in the past three
decades [5]. Microscopic aspiration of subglottic contami-
nated secretions into the lower respiratory tract is considered
as an important mechanism in the pathogenesis of VAP
[3]. Impairment of laryngeal function by the endotracheal
tube is the particular risk among intubated patients receiving
MV [4]. Therefore, VAP prevention should be focused on
aspects of care affecting this process. Staphylococcus aureus
(S. aureus) is the main pathogen responsible for VAP and the
leading cause of death among all ICU-acquired infections [6].
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A preventive method to avoid the progression of subglottic
secretions into the lower respiratory tract is subglottic secre-
tion drainage (SSD) which removes secretions using Hi-Lo
Evac endotracheal tube (Hi-Lo Evac; Mallinckrodt, Athlone,
Ireland; Evac ETT) [7]. Evac ETT is a new and special tracheal
tube with a separate dorsal suction lumen which is used
for evacuation of subglottic secretions. The suction lumen
of Evac ETT has two ports: a subglottic port located 15mm
above the cuff with an elliptical shape (major axis: 6mm,
minor axis: 3mm) and an external port for connection to
suction [8]. Although Evac ETT has been suggested to reduce
the risk of development of VAP [9–13], its failure has been
reported in some surveys [8, 14] as Girou and colleagues
reported that SSD had not decreased the airway colonization
[15]. The aim of the present study was to compare the inci-
dence of VAP in severely ill poisoned patients who had been
intubated by Evac ETT versus conventional endotracheal
tubes (C-ETT) in our toxicology ICU (TICU).
2. Materials and Methods
2.1. Study Design. This randomized clinical trial was con-
ducted on poisoned patients admitted to our 16-bed TICU
of Loghman Hakim Hospital Poison Center (LHHPC) from
August 2012 to March 2013. The study was approved by the
research ethics committee in ResearchDeputyDepartment of
the Shahid Beheshti University of Medical Sciences, Tehran,
Iran.
2.2. Intervention. Patients older than 18 years of age poisoned
by any medication or chemical agent who needed intubation
and MV and had been admitted to our TICU within the
period of the study were included. Indications for intubation
were profound disturbance in consciousness with the inabil-
ity to protect the airway, severe pulmonary or multisystem
injury associated with respiratory failure, loss of gag/cough
reflex, airway obstruction, and anticipated loss of control of
the airway. Indications for MV were ventilation and oxy-
genation failure. Those younger than 18 years, patients with
the history of acquired immunodeficiency syndrome, lung
cancer, chronic obstructive pulmonary disease, immunosup-
pressive therapy, and pregnancy, and cases who had received
antibiotics within the last 24 hours before admission were
excluded.
Finally, 100 eligible patients with an expected duration of
mechanical ventilation of more than 48 hours were recruited
in the study and randomly assigned into two groups: (1) sub-
glottic secretion drainage (SSD) group who were intubated
by Evac ETT (case group; 𝑛 = 50) and (2) control group
who were intubated by conventional ETT (𝑛 = 50). The
SSD procedure was performed intermittently with one-hour
intervals using a 10 mL syringe. In both groups, internal
diameter of the ETT was 7 to 7.5mm for women and 8 to
8.5mm for men and the ETT was inserted to the 23 cm line
in men and 21 cm line in women. Neither oral chlorhexidine
nor oral antibiotic pastes were administered. All patients
received pantoprazole for stress ulcer prophylaxis. All cases
were followed up every day by a well-trained ICU nurse until
discharge from the TICU.
2.3. Vigilance against Microbiological Threats: Diagnosis of
VAP. Diagnosis of VAP was confirmed by radiographic lung
infiltration with at least two of the following criteria: (1)
core temperature higher than 38∘C or lower than 35∘C, (2)
leukocyte count higher than 10000/𝜇Lor lower than 4000/𝜇L,
(3) presence of new purulent respiratory secretion or any
changes in the sputum, (4) significant quantitative culture of
respiratory secretions by tracheal aspirate (>106 cfu/mL), (5)
detection of rales or dullness on chest examination, and (6)
at least 10% decrease in arterial pO2 [7, 16]. Diagnosis and
treatment of VAPwasmade by an infectious disease specialist
who was blind to the treatment assignment.
2.4. Variables Recorded. Demographic characteristic and
clinical and paraclinical data including age, gender, mental
status by Glasgow coma scale (GCS), type of poisoning, time
elapsed between exposure and admission, on-admission vital
signs, tracheotomy, reintubation, and type and duration of
antibiotic therapy were recorded in a self-made question-
naire.
Incidence of VAP (per ventilated patients), duration of
mechanical ventilation, length of ICU stay, length of hospital
stay, and mortality rate were also recorded as the outcome
measurements of the patients and evaluated.
2.5. Statistical Analysis. Normality of data in quantitative
variables was checked by Shapiro-Wilk test and data Q-Q
plot. To evaluate the changes between groups in nominal
variables, we used Chi-square or Fisher’s exact test. 𝑡-test and
Mann-Whitney 𝑈 test were used to evaluate the difference
between groups in quantitative variables. A 𝑃 value less than
0.05 was considered to be statistically significant. Statistical
analysis was performed by statistical package for social
sciences (SPSS) version 21.0 (IBM Co, Chicago, Ill, USA).
3. Results
Seven and two patients in the case and the control group
self-extubated themselves in less than 24 hours, did not
need reintubation, and were therefore excluded. A total of 91
patients (43 in the Evac-ETT and 48 in the C-ETT groups)
were finally included, of whom 56 (61.5%) were male and
35 (38.5%) were female. Mean age was 28.64 ± 12.05 and
38.66 ± 14.98 years in case and control groups, respectively,
Table 1.There was no significant difference between these two
groups regarding age, sex, time elapsed between exposure and
admission, vital signs on admission, and type of poisoning
(all 𝑃 values were higher than 0.05), Table 2. Median GCS
was 7 and 8 in the case and control groups, respectively.Mean
duration of intubation was 4.5 ± 3.9 days (median [IQR]: 3
days [0.3–14 days]) and 3 ± 2.5 days (median [IQR]: 2 days
[0.3–11 days]) in case and control groups, respectively (𝑃 =
0.03), Table 1. Accidental extubation was reported in 11 cases
and 21 controls (𝑃 = 0.037).Three patients in each groupwere
reintubated during the study period.Mean ICU length of stay
was 7±6.3 days in cases (median [IQR]: 5 days [0.5–30 days])
and 4.8 ± 4.7 days in controls (median [IQR]: 3.1 days [0.7 to
30 days]; 𝑃 = 0.98). VAP was detected in 24 of 43 (55.8%)
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Table 1: Results.
Variables Case group (Evac ETT) Control group (C-ETT) 𝑃 value
Mean duration of intubation (days) 4.5 ± 3.9 3 ± 2.5 0.03
Accidental extubation 11 21 0.037
Mean ICU length of stay 7 ± 6.3 days 4.8 ± 4.7 0.98
VAP 55.8% 47.9% 0.45
Mean age (years) 28.64 ± 12.05 38.66 ± 14.98
Table 2: Comparison of sex, age, vital signs on admission, and time elapsed between exposure and admission between the case and control
groups.
Variables Case group (Evac ETT) Control group (C-ETT) 𝑃 value
Male 26 (60.5%) 30 (62.5%) 0.84∗
Female 17 (39.5%) (37.5%)
Age 35.4 ± 13.7 32.2 ± 15.2 0.16‡
Systolic blood pressure 109 ± 20 117 ± 25 0.09†
Temperature 37 ± 1 37 ± 1 0.97‡
Pulse rate 93 ± 21 99 ± 26 0.2†
Time elapsed between exposure and admission 5.7 ± 6.2 4.5 ± 4.7 0.27‡
†Based on 𝑡-test. ‡Based on Mann-Whitney test. ∗Based on Chi-square test.
patients in the case group and 23 of 48 (47.9%) patients in
the control group (𝑃 = 0.45), Table 1. VAP incidence and
ICU length of stay were not significantly different between
the two groups, but duration of intubation was. In 47 of
the available specimens, a total of 60 bacterial isolates grew.
Quantitative cultures reached the 106 cfu/mL (threshold of
positivity for respiratory secretions) in 47 (51.65%) patients
(positive cases) and were below this threshold in 44 (48.35%)
patients (negative cases). The cultures were mono-microbial
in 35 patients yielding 35 isolates and poly-microbial in 13
patients yielding 26 isolates. Mean duration of antibiotic
therapy was 6.3 ± 2.4 and 5.7 ± 2.1 days in case and control
groups, respectively. Tracheostomy was performed in three
patients and one of them was in the case group. Mortality
rate was 4.7% and 8.3% in the cases and controls. Although
mortality rate was less in the case group, this difference was
statistically insignificant (𝑃 = 0.68).
4. Discussion
VAP is the leading cause of poor outcome, morbidity, and
high mortality rate in ICUs [1]. The European Prevalence
of Infection in the Intensive Care study reported that VAP
was 45% of all ICU-acquired infections in European ICUs
[17]. Differences in the study population, definitions, and type
of hospital or ICU were reasons of the wide VAP incidence
variation from 7% to 70% [1]. In the present study, most of the
patientsweremale and youngwhich is completely predictable
in TICU [1].
We used quantitative cultures of the homogenized EA.
Despite newer invasive bronchoscopic methods available to
diagnose VAP, many physicians use quantitative culture of
the endotracheal aspirates with a cut-off point of 106 cfu/mL.
Good correlations have been found between the results
of quantitative cultures of protected specimen brush or
bronchoalveolar lavage and those of quantitative cultures of
EA [18]. According to our results, themost frequently isolated
microorganisms were S. aureus (54.10%) and Acinetobacter
spp. (19.68%). This is in accordance with previous studies
which showed that S. aureus was the most common isolate
from ICU patients with nosocomial pneumonia [19–21].
The incidence of VAP was 55.8% (per ventilated patients)
in cases and 47.9% in controls (𝑃 > 0.05). Comparison of the
other outcomes such as ICU length of stay and mortality rate
showed no significant difference between these two groups,
either. Likewise, three other studies found that SSD did not
decrease the incidence of VAP or airway colonization [15, 22–
24]. In a randomized controlled trial on 343 cardiac surgery
patients, no significant difference was found in frequency of
VAP with or without continuous microaspiration of subglot-
tic secretions (CASS).
There were no differences in hospital mortality, overall
duration of MV, or length of hospital stay, either, although
episode of VAP occurred significantly later in the group
receiving CASS compared to the group without CASS [22].
Subglottic drainage, however, was shown to reduce VAP
rates in some other studies; therefore, these investigations
suggested using an orotracheal tube that enabled continuous
or intermittent subglottic suctioning, especially in patients
who might require intubation for 48 hours or longer [23, 24].
A meta-analysis in 2005 evaluated 896 patients from five sur-
veys and showed 49-percent reduction in risk of VAP using
SSDbutwithout any differences in other outcomes.This study
also suggested that SSD might not be effective in patients
requiring less than 72 hours of MV likely because several
days are required for the accumulation of contaminated
subglottic secretions and their subsequent microaspiration
[9].
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However, major disadvantages such as failure to aspi-
rate subglottic secretions with the Evac ETT and problems
with airway mucosal tissue were mentioned in some other
investigations [8, 14, 15]. Lack of a fiber-optic bronchoscope
for evaluating the subglottic part of the suction lumen was a
limitation of the current study. Another limitation was that
we did not compare the airway mucosal injury between the
two groups. Blinding process was another limitation because
Evac and conventional ETT are visually different and the
physicians could not be blinded to the groups; however, our
infectious disease specialist was blinded to the procedure of
the study.
5. Conclusion
The SSD procedure was performed intermittently with one-
hour intervals using 10mL syringe. Subglottic secretion
drainage does not significantly reduce the incidence of
VAP in patients receiving MV. This strategy appears to be
ineffective in preventing VAP among T ICU patients.
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